Creating Evidence-Based Ratings and Life Expectancies Medical Impairments [0.03%]
基于证据的评级和生活预期寿命医学损害
John R Iacovino
John R Iacovino
Accurate and profitable risk selection requires evidence-based survival information. Medical Impairment Manual (MIM) ratings and life expectancies can be determined from illustrated survival and/or mortality curves in the medical literature...
Natalia Reyes-Cancino,Elyssa Del Valle,Asha Sapre et al.
Natalia Reyes-Cancino et al.
Traditional cigarette smoking has declined markedly over recent decades due to increased health awareness, regulatory action, and public health campaigns. At the same time, alternative nicotine products, particularly e-cigarettes and oral n...
Timothy Meagher
Timothy Meagher
Interest in the concept of "biological age" has grown substantially in recent years. Longevity clinics and direct-to-consumer companies now promote biological age testing, often with the promise that targeted interventions can slow the agin...
Gina C Guzman,Tristan Walsh
Gina C Guzman
Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly expanded beyond their initial role in diabetes management, demonstrating therapeutic potential across a range of non-diabetic conditions. Due to their potential to improve morta...
Vera F Dolan
Vera F Dolan
Benzodiazepines are a class of tranquilizers that, like prescription opiates, are commonly subject to abuse. Abusers of benzodiazepines commonly malinger to sustain access to these prescriptions from their health care providers by creating ...
Between Fear and Adoption: The AI Paradox in Medico-Legal Practice Among National Insurance Physicians [0.03%]
恐惧与采纳之间：国民保险医师医法实践中的人工智能悖论
Eytan Ellenberg,David Amsalem,Eldad Katorza
Eytan Ellenberg
Objectives.—: To assess artificial intelligence adoption patterns, trust levels, and perceived utility among physicians conducting disability assessments for a national insurance system, with a focus on the paradox betwe...
Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022 [0.03%]
基于年龄、种族/民族、临床分期、病理分级、疾病持续时间及诊断入组时期等的前列腺癌长期（1975～2022年）全病程生存队列系统综述分析：共648,114例患者的20年随访回顾性研究
Anthony F Milano
Anthony F Milano
Prostate cancer is a major cause of disease and mortality among older men (mean age 67.3 years old) in the United States and globally. Given the biological heterogeneity of this cancer in this short- and long-term United States retrospectiv...
Hazard Ratio to Life Expectancy: Gompertz-Makeham Validation of Emerging Risk Factors Collaboration Cardiometabolic Multimorbidity Tables [0.03%]
风险比转化为预期寿命：新兴危险因素协作项目心血管代谢性多病共存表的戈梅兹-麦基姆验证分析
Bernard Silke
Bernard Silke
Objective.—: To validate Emerging Risk Factors Collaboration (ERFC) high-risk cardiometabolic life years lost (LYL) tables using Gompertz-Makeham calibrated to hazard ratios, offering a reproducible framework for insuran...
David Wesley
David Wesley
A traditional print journal is not ideal for the dissemination of computer code and related data. Without the actual code and data, reproducibility cannot be assessed, and there can be no validation of the premise of such an article. Fortun...
When Is a Test "Genetic?" The Case of Multi-Cancer Early Detection Tests [0.03%]
多癌症早期检测筛查技术带来的伦理问题：基因渐变与遗传偏见
Timothy Meagher
Timothy Meagher
Multi-cancer early detection (MCED) tests are increasingly popular. Are these tests "genetic," and if so, can insurers use them in the risk assessment process? This article reviews definitions of genetic tests. It then reviews the motivatio...